- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04470908
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
March 10, 2023 updated by: BeiGene
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of the Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Male Subjects
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
- Covance Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Males of any race, between 18 and 65 years of age, inclusive.
- Male participants in good health as determined by past medical history, physical examination, vital signs, ECG and laboratory tests at screening
- Must have a body mass index (BMI) between 18 and 32 kg/m^2
Key Exclusion Criteria:
- Participants with a clinically relevant history or presence of any clinically significant disease
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
- History of drug or alcohol abuse within 1 year prior to check-in
- Use or intended use of any nonprescription medications/products including vitamins, minerals, herbal/plant-derived preparations within 7 days prior to check-in
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result and/or a positive human immunodeficiency virus (HIV) at screening
- Use of tobacco- or nicotine-containing products within 3 months prior to check-in
- Use or intended use of any prescription medications/products within 14 days prior to check-in
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zanubrutinib + Rifabutin
Day 1: zanubrutinib Days 3 to 10: rifabutin Day 11: zanubrutinib and rifabutin |
Single oral dose of 320 mg
Other Names:
Oral dose of 300 mg once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Apparent Oral Clearance (CL/F) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Apparent Volume of Distribution (Vz/F) of Zanubrutinib
Time Frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: From the date of first study drug administration to 30 days after last dose (up to 3.5 months)
|
Adverse events (AEs) and serious adverse events included for summary, AEs that start during or after the first dose, or start prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters
|
From the date of first study drug administration to 30 days after last dose (up to 3.5 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Study Director, BeiGene
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 29, 2020
Primary Completion (Actual)
November 10, 2020
Study Completion (Actual)
November 10, 2020
Study Registration Dates
First Submitted
July 10, 2020
First Submitted That Met QC Criteria
July 10, 2020
First Posted (Actual)
July 14, 2020
Study Record Updates
Last Update Posted (Estimated)
December 14, 2023
Last Update Submitted That Met QC Criteria
March 10, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BGB-3111-112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Zanubrutinib
-
Zhang Lei, MDRecruitingThrombocytopenia | Antiphospholipid Syndrome | TreatmentChina
-
Fudan UniversityRecruiting
-
Xuanwu Hospital, BeijingRecruitingNeuromyelitis OpticaChina
-
Zhang LeiRecruitingImmune Thrombocytopenia | TreatmentChina
-
Matthew C. BakerStanford UniversityRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNot yet recruitingLymphomaNorway, Netherlands, Denmark, Belgium
-
The First Affiliated Hospital of Soochow UniversityRecruitingUntreated Mantle Cell LymphomaChina
-
Huazhong University of Science and TechnologyRecruitingDiffuse Large B Cell LymphomaChina
-
UMC UtrechtBeiGeneNot yet recruitingMonoclonal Gammopathy of Uncertain SignificanceNetherlands
-
Fudan UniversityRecruitingMantle Cell Lymphoma | Maintenance TherapyChina